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ABSTRACT: Protocols for activity aiming at early
diagnosis and treatment of inherited breast or breast-
ovarian cancer have been reported.  Available reports
on outcome of such programmes are considered here.
It is concluded that the ongoing activities should
continue with minor modifications.  Direct evidence
of a survival benefit from breast and ovarian screening
is not yet available.  On the basis of expert opinion
and preliminary results from intervention programmes
indicating good detection rates for early breast cancers
and 5-year survival concordant with early diagnosis,
we propose that women at high risk for inherited
breast cancer be offered genetic counselling, education
in ’breast awareness’ and annual mammography and
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clinical expert examination from around 30 years of
age.  Mammography every second year may be
sufficient from 60 years on.  BRCA1 mutation carriers
may benefit from more frequent examinations and
cancer risk may be reduced by oophorectomy before
40–50 years of age.  We strongly advocate that all
activities should be organized as multicentre studies
subjected to continuous evaluation to measure the
effects of the interventions on long-term mortality, to
match management options more precisely to
individual risks and to prepare the ground for studies
on chemoprevention.
The Biomed 2 Demonstration Programme on
Inherited Breast Cancer has compiled the results
of the ongoing prospective studies, leading to the
first report on outcome of early diagnosis and
treatment of inherited breast cancer evaluated by
survival after diagnosis [18].  5-year event-free
survival after diagnosis is 86%, which is
substantially better than all retrospective reports
on prognosis of inherited breast cancer diagnosed
outside specific follow-up programmes.
Retrospective reports on age at onset of inherited
breast cancer [3,5,10] were verified by the
prospective studies.  It was demonstrated that, in
families ascertained through clinical criteria, new
breast cancers arise at a greatly increased rate
(compared to the general population) in women
aged 30 years or more [13,15,17], and it was
verified that, in the subgroup of breast-ovarian
cancer kindreds, the majority of such cancers
occur in BRCA1 mutation carriers [1].  It was
found that uptake of genetic testing in kindred
with demonstrated BRCA1 mutations can be as
high as 80% without measurable negative effects
on quality of life [22].  Different centres made
similar use of cytology/biopsy, resulting in a
diagnosis of cancer in 11–17% of all such
procedures [19].  Comprehensive economic
evaluation resulted in an estimated cost of Euro
750–1600 per life year gained through early
diagnosis and treatment [11].
In BRCA1 mutation carriers, breast cancer
tends to be diagnosed as infiltrating estrogen
receptor negative cancers with histopathological
signs of unfavorable prognosis [1,12,14,23].  It is
not demonstrated, but it is suggested, that this
subgroup may benefit from more frequent
follow-up examinations.
Prophylactic mastectomy is discussed
separately [9].  Results of tamoxifen chemo-
prevention trials to avoid breast cancer are
inconclusive.  Prophylactic oophorectomy may
reduce breast cancer risk in BRCA1 mutation
carriers, and use of hormone replacement therapy
may not negate this effect [21].  Ongoing studies
on the risk of contralateral cancers in BRCA1/2
mutation carriers, will indicate whether or not
tamoxifen and/or chemotherapy may prevent
breast cancers in mutation carriers.  Oral
contraceptive use reduces the risk of inherited
ovarian cancer [20], but may not be
recommended until the potential effect of
increasing the breast cancer risk has been
evaluated.  Insurance issues related to predictive
testing are discussed separately [16].  Modalities
for treatment of demonstrated inherited breast
cancer are discussed separately [7].
Mutations in BRCA1 and BRCA2 are
associated with substantial risk of ovarian cancer.
Retrospective studies indicate that ovarian cancer
in BRCA1 mutation carriers occurs from 40 years
of age on [5], while the risk is lower and the
onset tends to be later in BRCA2 mutation
carriers [10].  Prospective series confirm that
breast cancer kindreds with two or more ovarian
cancers, and/or cases with both breast and
ovarian cancers, were likely to be caused by
BRCA1 mutations, that ovarian cancers
prospectively detected were rarely seen before 40
years of age, and that almost all ovarian cancers
occur in BRCA1 mutation carriers [1,4].  No
study on early diagnosis of inherited ovarian
cancer has demonstrated safety: conversely,
experience in several centres indicates an un-
favourable prognosis for prospectively diagnosed
cancers.  Formal survival analyses from these
series are not known to us.  Infiltrating cancer has
been found in ovaries prophylactically removed
from patients declared to be disease-free by the
operating gynaecologist [2].  Although a limited
number of peritoneal carcinomatoses histopatho-
logically classified as ovarian cancers have been
reported after prophylactic oophorectomy, the
preventive effect of prophylactic oophorectomy
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is judged to be good.
Based on these observations we advocate that
the ongoing health programmes in most countries
may continue essentially as they are carried out
today [6,8,24] and with modifications as
indicated below.
SUGGESTED GUIDELINES
Definition of women at high risk for inherited
breast cancer
• A family history of two or more first degree
relatives (or second degree relatives though
males) with early onset (< 50 years) breast
cancer, and/or
• Multiple cases of breast cancers in the same
lineage compatible with dominant inheritance
in the family, and/or
• A combination of early onset breast cancer
and ovarian cancer in the family, and/or
• Li Fraumeni syndrome (SBLA) or Cowden
disease family, and/or
• Demonstrated BRCA1/2 truncating mutation
or TP53 or PTEN mutation.
• Males with BRCA2 truncating mutation are
also considered to be at risk.
Genetic counselling
Each woman at risk of inherited breast cancer
should be entitled to genetic counselling by a
specially trained doctor or genetic counsellor
after validation of the family history and before
risk estimates are finalized.  The need for
specially designed health care programmes
should be determined and discussed in the course
of such counselling.  Predictive genetic testing
should be carried out under strict quality control,
with pre- and post-test genetic counselling by the
responsible medical geneticist or associated
genetic counsellor, and respecting the privacy
and individual rights of each single patient.
(Guidelines for these activities and the
complicated problems related to sharing of
family information between family members, are
discussed separately.) Demonstrated high risk for
inherited breast cancer should ensure access to
the health care programmes suggested below,
pending direct evidence of a survival benefit but
on the assumption that this will emerge from
presymptomatic detection of breast cancers.
Follow-up examinations
• Annual mammography and clinical expert
examinations from 30 years of age (some
centres modify starting age according to age of
onset of disease in affected relatives). From 60
years of age mammography every second year
(screening mammography) may be
sufficient.  Outside very high-risk families
(BRCA1/2 carriers or clearly dominantly
inherited disease in the kindred) more limited
screening such as annual 35–50 years and 18
monthly to 60 years may be appropriate.
• BRCA1 mutation carriers (demonstrated or
assumed by family history of two or more
ovarian cancers and/or one relative with both
breast and ovarian cancer) may benefit from
mammography and clinical expert examina-
tions twice a year and, where facilities permit,
this option should be evaluated.
• Monthly self-examination or “breast aware-
ness” education should be encouraged.
Prophylactic surgery
• BRCA2 mutation carriers (demonstrated, or
strongly indicated by male breast cancer, plus
other relevant cancers, in the family) may
benefit from oophorectomy at menopause (45–
50 years of age)
• BRCA1 mutation carriers (demonstrated or
strongly indicated by two or more ovarian
cancers and/or one with both breast and
ovarian cancer in the family) may benefit from
oophorectomy at 35–50 years of age.  Those
not choosing oophorectomy should be offered
follow-up including regular transvaginal
ultrasound examination.
• Indications for prophylactic mastectomy are
not considered here but should be subject to
continuing evaluation.
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Monitoring and evaluation of activity
To evaluate the effect of screening and
preventive activities, it is of the utmost impor-
tance that they are carried out as prospective
multicentre studies subjected to strict protocols
and continuous evaluation.  This is essential not
only to establish the effect of such interventions,
but also to generate data from which screening
and/or intervention strategies can be matched
more precisely to individual estimates of risk and
to provide the background necessary for
assessment of new chemopreventive modalities
in the near future.
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